BBNX - Earnings announcements

IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026. First Quarter 2026 Financial Highlights & Key Metrics Net sales of $27.6 million, up 57% compared to $17.6 million in the first quarter of 2025. Durable Medical Equipment (DME) channel net sales of $16.9 million, up 22% compared to $13.8 million in the first quarter of 2025.Pharmacy Benefit Plan (PBP) channel net sales of $10.7 million, up 181% compared to $3.8 million in the fir

IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2026 financial results after the financial markets close on Tuesday, April 21, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's first quarter 2026 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2025 and introduced its annual guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial Highlights & Key Metrics Net sales of $32.1 million, up 57% compared to $20.4 million in the fourth quarter of 2024. Durable Medical Equipment (DME) channel net sales of $22.3 million, up 24% compared to $18.0 million in the fourth quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $9.8 million, up 295% compared to $2.5 mill

IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2025 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archi

IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025. Members of the Company's management team will host in-person meetings in San Francisco, CA from January 12, 2026 through January 14, 2026 to discuss preliminary topline fourth quarter 2025 financial results and key metrics set forth below. The Company invites investors to register for in-person meetings by contacting the Company's investor relations representative at ir@betabionics.com. Preliminary, Un

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Third Quarter 2025 Financial Results & Key Metrics Net sales of $27.3 million, up 63% compared to $16.7 million in the third quarter of 2024. Durable Medical Equipment (DME) channel net sales of $21.0 million, up 45% compared to $14.5 million in the third quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $6.2 million, up 178% compared to $2.2 million in the thir

IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2025 financial results after the financial markets close on Tuesday, October 28, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following

IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Second Quarter 2025 Financial Results & Key Metrics Net sales of $23.2 million, up 54% compared to $15.0 million in the second quarter of 2024. Durable Medical Equipment (DME) channel net sales of $18.6 million, up 31% compared to $14.3 million in the second quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $4.6 million, up 498% compared to $0.8 million in the second

IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2025 financial results after the financial markets close on Tuesday, July 29, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following l

IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live c

IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived